Brexit Impact On Pharmacovigilance Depends On UK MHRA’s Access To EU Databases And Systems
Executive Summary
The UK’s current oversight of pharmacovigilance systems is dependent on its access to several databases and centralized systems designed to serve the single EU market. If the UK cannot have continued access to these systems post Brexit, companies may face duplicative requirements and greater workload.
You may also be interested in...
Modernized Pharmacovigilance Database Nears In Switzerland
Switzerland is on track with plans to adopt a new modernized pharmacovigilance system with enhanced data analysis capabilities. The new system will not result in any changes to how companies and healthcare professionals report adverse drug reactions to Swissmedic.
Swissmedic kicks off pharmacovigilance database modernization plans
Switzerland’s healthcare product regulator, Swissmedic, is planning to replace the pharmacovigilance database it currently uses with a modern system by the end of 2017 and has issued a request for information on the project from software suppliers1.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.